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Abstract 34 
 35 
Objectives: The aim of this study was to identify domains that determine quality of life in patients with 36 
peripheral arterial disease (PAD) and find the patient reported outcome measures (PROMs) that can 37 
examine the identified themes.  38 
Methods: A systematic review of all the main six databases was undertaken to identify primary 39 
TXDOLWDWLYHVWXGLHVUHSRUWLQJRQ3$'SDWLHQWV¶KHDOWKDQGRUTXDOLW\RIOLIHQuality of studies was 40 
assessed using the CASP criteria. Findings from the included studies were analysed using 41 
Framework Analysis methodology. The identified themes were mapped against the items/domains of 42 
validated patient reported outcome measures (PROMs) used in patients with PAD.  43 
Results: 44 
The systematic review identified eight papers that fulfilled the inclusion criteria. The included papers 45 
reported the views of 186 patients with PAD including patients with intermittent claudication, critical 46 
ischaemia and amputation secondary to PAD.. The overall quality of the included studies was good 47 
based on CASP criteria.  Framework Analysis identified thirty-five themes that were divided into six 48 
main groups: symptoms, impact on physical functioning, impact on social functioning, psychological 49 
impact, financial impact and process of care.. The best fit generic and disease specific PROMs were 50 
Nottingham health profile (NHP) and Vascular quality of life questionnaire (VascuQoL) respectively. 51 
None of the PROMs covered all the themes important to patients with PAD.  52 
Discussion:  53 
The findings from the review identified the important domains that affect patients living with PAD None 54 
of the current generic and disease specific PROMs provide a comprehensive measure for all themes 55 
that impact the daily living of patients with PAD.  56 
 57 
 58 
Key messages: 59 
- Peripheral arterial disease is a spectrum of conditions ranging from asymptomatic disease 60 
and minor claudication to limb loss.  61 
- Understanding and measuring quality of life in these patients is of paramount importance to 62 
guide intervention. 63 
- This systematic review is the most comprehensive attempt in measuring the impact of this 64 
disease in its different manifestation and can help improve current measures that are used to 65 
measure quality of life.   66 
Introduction 67 
 68 
Population studies suggest that 1 in 5 people above the age of 60 have some degree of peripheral 69 
artery disease (PAD) in the lower limbs. The incidence of this disease increases with age (1). Most 70 
patients with PAD are asymptomatic however patients can present with a spectrum of symptoms, 71 
reflecting different stages of the disease. The most common clinical presentation is intermittent 72 
claudication (IC), which is pain in the leg on walking; only 20% of these patients develop severe 73 
symptoms of critical limb ischaemia (CLI) (2). Patients with CLI can present with rest pain, non-74 
healing leg ulcers or gangrene; if they do not receive treatment they may lose part of their lower limbs 75 
(3,4). Patients with CLI have a high risk of mortality with nearly 25% dying and 30% requiring major 76 
lower limb amputation within one year (5,6). Symptomatic PAD results in significant functional 77 
limitations and reduced health-related quality of life (HRQoL) in affected patients (5).  78 
PAD is a chronic disease and patients suffering with this condition need support to choose the best 79 
treatment strategy to reduce the impact on their quality of life. HRQoL can be measured using either 80 
generic or disease specific patient reported outcome measures (PROMs). Patient choice over 81 
treatment and care is a central feature of most advanced health care systems, it is proposed that 82 
information gathered by PROMs from patients directly can help inform the choice of treatments and 83 
promote equity as well as excellence (7).  84 
Patients' experience of treatment and care is a major indicator of quality and there has been a huge 85 
expansion in the development and application of PROMs. These instruments examine the most 86 
important issues to the patients by asking them directly about any changes. PROMs provide an 87 
insight into the way patients perceive their health and the impact that treatments have on their quality 88 
of life.  89 
The aim of this study was to systematically review the qualitative evidence of SHRSOH¶VH[SHULHQFHVRI90 
living with PAD. The identified domains were then mapped against the items/domains of identified 91 
validated generic and disease specific PROMs (8). The intention was to find the PROMs that captured 92 
the most important issues to patients with PAD.  93 
Method 94 
The review aimed to find all the primary qualitative research studies (interview and/or focus groups) 95 
that explicitly investigated the impact of PAD on daily living, health and quality of life. The inclusion 96 
criteria included any patients with PAD (IC, CLI, ischaemic ulceration, necrosis, gangrene and 97 
amputation due to PAD).  Any studies with undefined population or mixed population that included the 98 
views from patients not suffering with PAD were excluded.  99 
For further information regarding the inclusion and exclusion criteria refer to table 1.  100 
This systematic review was undertaken and reported in accordance with the general principles 101 
recommended in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 102 
(PRISMA) statement. In accordance with the study protocol 103 
(https://www.sheffield.ac.uk/polopoly_fs/1.552397!/file/DP_16_05.pdf) (9), searches were conducted 104 
from inception up to April 2017 in bibliographic databases including CINAHL via EBSCO, Medline and 105 
Medline in Process via Ovid, Embase via Ovid, PsycINFO via Ovid, Social Science Citation Index/ 106 
Science Citation Index via Web of Science (Thomson Reuters) and Proquest dissertations and 107 
theses. No language or date constraints were applied.  108 
 Insert Table 1 109 
 110 
The search strategy combined condition terms, terms for patient views and terms for qualitative 111 
studies (which augmented a qualitative study filter) (9). Further details of the search strategy are 112 
provided in Appendix 1 (supporting information).  113 
 114 
Study selection 115 
The search results were entered into Endnote X8 Thomson Reuters, Philadelphia, USA), two 116 
reviewers (AA, PP) independently screened the titles for inclusion and exclusion in accordance with 117 
the set criteria in the protocol. All titles were examined, and any citations that clearly did not meet the 118 
inclusion criteria (for example mixed population, quantitative PROMs data, unrelated to PAD) were 119 
excluded. For included titles, abstracts were read and for the included abstracts, full-text articles were 120 
obtained.  121 
 122 
Quality assessment 123 
The Critical Appraisal Skills Program (CASP) qualitative checklist instrument was used to assess the 124 
methodological quality of the included studies in the review (10). This was selected as it assesses 125 
both the appropriateness and the quality of reporting of the studies included and is commonly used in 126 
qualitative reviews of evidence (11). CASP consists of ten questions about the qualitative 127 
methodology that are answered either as yes, no or unclear. Two of the authors (AA, EL) 128 
independently examined the quality of each study and any inconsistencies were resolved by 129 
discussion or involving a third author (GJ).   130 
 131 
Data extraction and analysis 132 
The data on authors, year of publication, country of study, number of participants, research aims, 133 
methods of recruitment, method of data collection, key results and analysis were extracted and 134 
tabulated for all the included studies. The first author (AA) uploaded all the papers into the qualitative 135 
data analysis software NVIvo10 (QSR International, Doncaster, Victoria, Australia) and the primary 136 
and secondary text (patient quotes reported in the articles and themes), were analysed. Framework 137 
Analysis was used to identify common and variable themes within the text of each article (12). The 138 
first stage of the analysis was undertaken by reading all the included papers to identify common terms 139 
and themes from within and across the articles. The second stage involved identifying a thematic 140 
framework by creating an initial coding scheme for the main themes; and eventually creating an index 141 
of themes. In the third stage the thematic framework was applied to all the primary and secondary 142 
data in the included papers. A framework matrix was created to arrange the data per the thematic 143 
references in the fourth stage. In the fifth and final stage themes were examined for their conceptual 144 
similarities and differences (Mapping and interpretation stage). A second reviewer (EL) checked all 145 
the themes that were identified and differences in conceptualization were discussed and adjusted. 146 
 147 
Triangulation of PROMs items with qualitative themes 148 
To examine the extent to which the items within generic and PAD disease specific PROMs 149 
corresponded to themes from the qualitative review a triangulation approach was followed (13,14).  150 
The items from generic and disease specific PROMs validated in patients with PAD (8) were 151 
examined in detail. The items from these instruments were mapped against the themes identified, and 152 
two researchers(AA, EL) reviewed both the themes from the qualitative review and the PROM 153 
items/domains to evaluate whether the concepts were the same (agreement), offered similar concepts 154 
(partial agreement) or were not present (silence). The aim was to identify whether any of the 155 
LQVWUXPHQWVFRYHUHGDOOWKHLPSRUWDQWLVVXHVIURPWKH3$'SDWLHQWV¶SHUVSHFWLYH 156 
 157 
Results 158 
 159 
The database searches identified 1113 citations; after removing duplicates, 779 titles were assessed 160 
and subsequently 65 full-text papers were reviewed in detail. Finally, only 8 papers fulfilled the 161 
inclusion criteria and were included in the qualitative evidence synthesis (Please see PRISMA chart 162 
(Figure 1)). Characteristics and main findings of the studies included in the qualitative synthesis are 163 
summarized in table 2.  164 
Insert Table 2 165 
Two of the studies were conducted in the UK (15, 16), three in Sweden (17-19) and three in the 166 
United States (20-22). The studies were published between 1998 and 2015; the mean age of the 167 
participants in the included studies ranged from 64-77, and the percentage of male participants was 168 
50-79%. The included studies reported the views of 186 patients with PAD including patients with 169 
intermittent claudication (IC), critical limb ischaemia (CLI) and amputation of lower limbs due to PAD.  170 
 171 
Quality assessment  172 
The overall quality of the included studies was good and all the studies scored ³yes´IRUDOPRVWDOOWKH173 
criteria set in the CASP checklist (10); however, four studies scored ³FDQ¶WWHOO´regarding 174 
consideration of the relationship between participants and researcher (16, 19-21). Only one study 175 
VFRUHGµFDQ¶W WHOO¶ZKHQDVVHVVLQJLIWKHUHFUXLWPHQWVWUDWHJ\ZDVDSSURSULDWHWRWKHDLPVRIWKH176 
research (20). For further detail on the quality of the included studies please see appendix 2. 177 
Analysis  178 
The Framework Analysis of the primary and secondary data in the included papers identified six main 179 
issues including symptoms, physical functioning, impact on social functioning, psychological impact, 180 
financial impact and process of care. In total thirty-five themes were identified. Table 3 shows the 181 
themes and subthemes and the sources from the included papers in this review.  182 
Insert Tables 3  183 
Symptoms 184 
 185 
This theme included several subthemes such as pain, altered sensation, cold extremities, weakness, 186 
mobility, ulcers, sexual functioning and symptom progression.  187 
Pain 188 
 189 
This was identified in all the included papers, severity of the disease resulted in different experiences 190 
of pain and this was reflected in the pain subthemes.  191 
Patients described different experiences with the initial appearance of the symptoms. Pain was most 192 
commonly described as discomfort, ache, cramp and creeping feelings of fatigue that got worse the 193 
farther they walked.  194 
³, JHWDFUDPSLQJLQWKHOHIWFDOI´³0\OHJVJHWWLUHG,FDQIHHOLWLQP\WKLJKV´ (21) 195 
³,JHWWKLVWHUULEOHFUDPSLQP\OHJVDQGWKHQ,GRQ¶WNQRZZKHUHWRJR´ (17) 196 
The description of pain in the legs and feet was different for patients with CLI. Some of these patients 197 
described rest pain and burning sharp pain in their feet and legs. Patients with vascular related 198 
amputation described the same type of continuous rest pain prior to their amputation.  199 
 200 
³,I,FRXOG,ZRXOGKDYHWDNHQDQD[HDQGFKRSSHGRIIP\OHJVRRQHUMXVWWRJHWULGRIWKHSDLQ³ 201 
³:KHQDVNHGRISDWLHQWVIHOWWKDWLQWROHUDEOHLVFKHPLFUHVWSDLQLVWKHPRVWDSSURSULDWHWKUHVKROG202 
for having their limb amputated, as opposed to ulceration, gangrene, or when their physician stated 203 
that OLPEVDOYDJHZDVQRORQJHUSRVVLEOH´ 204 
³,GHILQLWHO\ZRXOGKDYHKDGWKHDPSXWDWLRQDWWKHVDPHWLPHSRLQW0\SDLQJRWVREDG,FRXOGQRW205 
ZDON´ (25) 206 
Rest pain was also reported to be particularly troublesome during the night causing sleep 207 
disturbances. Patients had to adapt their position to deal with this pain. Some reported sleeping in a 208 
chair to overcome the severity of this pain. 209 
³([SHULHQFHVVXFKDVEHLQJIRUFHGWRVLWLQDFKDLUGXULQJWKHQLJKWVWRVWDQGWKHSDLQFRQWULEXWHGWR210 
tiredness and feelingVRIH[KDXVWLRQ´ (17) 211 
³7KHJUHDWHVWEHQH¿WVRIUHYDVFXODULVDWLRQVZHUHWKHUHOLHIIURPSDLQWKHDELOLW\WRVOHHSDJDLQ´ (18) 212 
 213 
Patients with failed revascularisation and subsequent amputation reported pain at the site of 214 
amputated limb; however, the phantom pain experienced was tolerable compared to the ischaemic 215 
rest pain (22). Furthermore, patients who underwent revascularisation complained of some residual 216 
pain following the procedure. Participants in one study reported that they avoided exercise following 217 
their intervention and some believed that the pain on walking was an indication that activity causes 218 
damage to their muscles and legs (16).  219 
 220 
Altered Sensation 221 
 222 
Participants in five studies (15-17, 20, 21) reported altered sensation in the affected limb; these 223 
symptoms were experienced by patients prior to and following the procedures. The description of this 224 
DOWHUHGVHQVDWLRQUDQJHGIURPIHHOLQJ³DGHDGZHLJKW´, especially in patients with CLI (15), to a minor 225 
intermittent tingling feeling in patients with IC (21). Altered sensation secondary to revascularisation 226 
was caused by either nerve damage or swelling post interventions (16).  227 
Cold Extremities 228 
 229 
Patients with chronic severe lower limb ischaemia complained of cold feet and legs; some of these 230 
patients reported that despite revascularisation the symptom persisted (18). One participant described 231 
this symptom in the following terms: 232 
³,FDQJHWXSDQGZDONDOLWWOHDQGVRRQ<HV,KDYHWROLYHZLWKLW,W¶VVOHHSLQJQRZKHUHDQGLW gets 233 
FROGOLNHEXWZKHQ,¶PPRYLQJWKHFLUFXODWLRQLVEHWWHU6R,VHHWKDW,¶PQHYHUJRLQJWRJHWULGRILWEXW234 
,FDQOLYHZLWKLWEHFDXVHLWGRHVQ¶WKXUWLQWKDWZD\WKDWLWGLGEHIRUHWKHRSHUDWLRQ´ (18) 235 
In one study some participants experienced coldness in the affected limb pre-operatively, 236 
postoperatively and after discharge, however, it was worse before revascularisation (15). 237 
Weakness & Fatigue 238 
 239 
Weakness and fatigue was reported by participants in four studies (16, 17, 19, and 20). Some 240 
reported this symptom to be the first they experienced; describing fatigue on walking followed by pain 241 
and cramps the more they continued to walk (16, 19). Some experienced loss of power with 242 
worsening fatigue as the disease progressed and many complained that despite intervention the 243 
fatigue symptoms did not completely resolve. One patient described this this symptom in the following 244 
terms: 245 
³<HVLW¶VMXVWOLNHLWKDVWDNHQWKHVWUHQJWKDQGSRZHUIURPPH´ (17) 246 
Many patients described that PAD meant living with long term fatigue and powerlessness (17, 20). 247 
Mobility  248 
 249 
Mobility problems were found to be the most significant issue for PAD patients in all of the included 250 
studies. All the included studies in this review highlighted problems with mobility to be the most 251 
important issue experienced by patients with PAD. The impact on mobility differed per the type of 252 
symptoms experienced, and the severity of the disease.  The impact was worse in patients with CLI 253 
and amputees. Patients with IC reported reducing their walking to avoid the symptoms of pain. IC 254 
patients also reported employing specific strategies to avoid pain and discomfort on walking by 255 
stopping regularly, or avoiding walking uphill or upstairs (19-21).  256 
 257 
³,WGHSHQGVcompletely on how hard I walk. If I walk very slowly, I can go many, many blocks, more 258 
WKDQDGR]HQRUVR,I,ZDONDJJUHVVLYHO\,FDQVWDUWWRIHHOVRPHWKLQJLQPD\EHWZREORFNV´ (21) 259 
³,XVXDOO\VK\DZD\IURPSODFHVZKHUH,ZRQ¶WEHDEOHWRVLWGRZQDQGUHVW´ (21) 260 
 261 
Another patient reported:  262 
µµ<RX NQRZKLOOVDQGVWDLUVWKH\¶UHWKHZRUVW$QGFDUU\LQJWKLQJVXSWKHVWDLUVLVHYHQZRUVH´ (19) 263 
 264 
Patients with CLI felt that their personal independence was compromised due to their problems with 265 
mobility.  They felt the disease took away their ability to walk completely or reduced their walking 266 
ability. This meant for many of them limited daily activities such as housework, shopping and cleaning 267 
(17).   268 
Many patients used aids such as walking sticks, walking frames and sometimes wheelchairs to 269 
overcome issues with mobility; these changes occurred over a long time to adjust to the symptoms 270 
(18).  271 
Many patients with amputation secondary to PAD reported that problems with mobility had the biggest 272 
impact on their quality of life. The major issues with mobility included maintaining their balance, 273 
walking upstairs or up ramps. Most patients with amputations relied on using wheelchairs, even if they 274 
had prosthesis. Many also reported that they wished that they had met the prosthesis specialists prior 275 
to amputation, to prepare them for life after amputation (22). 276 
Non-healing ulcers 277 
 278 
One of the most distressing symptoms experienced by patients with CLI was non-healing ulcers or 279 
wounds. Patients used terms like µpainful¶ and µdisgusting¶ to describe their ulcers. Many were 280 
concerned about the shape and colour of their leg; the shape of the ulcer had an impact on the type of 281 
clothes and shoes they can wear. Several patients also complained of recurrent leg ulcers due to 282 
PAD. 283 
³,W¶VWURXEOHVRPHEHFDXVHLWUXQV7KDW¶VWKHKDUGWKLQJDQGVRPHWLPHVLWKXUWV,W¶VKDUGWRZHDU284 
VKRHV´ (17) 285 
³:HOOWKHGLVWULFWQXUVHFDPHDQGORRNHGDWLWDQGEDQGDJHGLW7KHQLWZDVDOOUight and then it came 286 
EDFNDQGWKHQLWZDVDOOULJKWDQGWKHQLWFDPHEDFNDJDLQVRLWLVWKHUHQRZ´ (17) 287 
Sexual functioning  288 
 289 
Some patients described a decline in their sexual functioning due to PAD. Although only a minority of 290 
patients reported that this was important to their overall quality of life. The decline in sexual function 291 
was associated with progression of symptoms of disease (22).    292 
Symptom Progression  293 
 294 
Participants in four studies understood that PAD is a chronic condition and that it can get worse (17, 295 
18 20, 21), some reported that they are focusing on avoiding progression of symptoms and worsening 296 
of PAD. Many SDWLHQWV¶ post-intervention adopted new strategies to avoid further intervention by 297 
modifying their lifestyle and giving up causative agents such as smoking (18). The perception of the 298 
amount of control participants had over their disease progression varied considerably across the 299 
studies. These perceptions ranged from having little or none, to having a great deal of control (20). 300 
Impact on Physical Functioning   301 
 302 
Participants in all the included studies described varying impacts on their ability to care for themselves 303 
independently (15-22), participate in exercise or perform their daily activities. The symptoms of pain 304 
and reduced mobility had the main impact on physical functioning (22). Patients with severe lower 305 
limb ischaemia also suggested that their physical function was affected by a lack of sleep due to their 306 
PAD symptoms, in addition to pain at rest or walking. (20).  307 
Impact of PAD on Social Functioning   308 
 309 
Seven studies described the impact of PAD impact on social life. Many patients reported that their 310 
social life was compromised including not being able to maintain their personal role, lack of support 311 
from their social circle, isolation and the inability to perform their hobbies. Problems with isolation and 312 
lack of social support were worse among patients with amputation secondary to PAD; many of these 313 
patients felt that a social support group may improve their quality of life (22). Patients with IC and CLI 314 
felt that their symptoms prevented them from keeping their hobbies, visiting family and friends and 315 
taking part in many activities that they enjoyed (15-21).  316 
Psychological Impact of PAD  317 
 318 
The papers reported that patients felt they had no control over their disease. This feeling was more 319 
common amongst patients who had revascularisation but still had some residual symptoms, or those 320 
that developed complications (16). Many patients suffered from low self-esteem, and felt embarrassed 321 
because of their symptoms; for example, some participants described feeling embarrassed because 322 
they stopped frequently to ease the pain. Some reported making up excuses to stop, for example 323 
pretending to be waiting for someone (19). Patients also suffered with issues of personal image and 324 
self-perception, with some patients feeling ³ROGEHIRUHtheir WLPH´ (19). Patients also reported the 325 
emotional burden of PAD with many experiencing low mood and a sense of loss due to the disease or 326 
its complications (16-21). Patients also reported symptoms of anxiety caused by fear of loss of 327 
independence, fear of amputation or fear of death (15-18, 20-22). 328 
Financial Impact of PAD  329 
 330 
One study described the impact of the disease on SDUWLFLSDQWV¶ employment, and their ability to carry 331 
out their tasks at work. Many participants in that study thought that these limitations may lead to job 332 
loss or the loss of opportunity to be promoted. Some patients planned to change jobs due to their new 333 
symptoms. (20).   334 
Process of Care 335 
 336 
 337 
All the studies reported that patients had limited understanding about the consequences of surgery. 338 
Patients with a diagnosis of IC and no intervention were not clear about their management, and did 339 
not understand why they were not offered interventions (15, 16). Many patients did not view walking 340 
as therapy for their disease, and therefore avoided walking as they believed the claudication pain was 341 
a sign of damage caused to the leg by walking (16).   342 
Many patients attempted to change their habits and devised strategies to manage their symptoms; 343 
this included alterations in walking by controlling pace, as well as planning stops for longer walks and 344 
taking pain relief (15, 16, 19). However, side effects of pain relief medications were a cause for 345 
restricted use (17). Some participants wished that their risk factors were modified earlier in the 346 
community including help to give up smoking (20).   347 
Post-amputation many participants felt that intolerable severe continuous ischaemic rest pain was the 348 
most appropriate threshold for amputation and saw no point in the revascularisation attempts at that 349 
stage. On patient said: 350 
³0RVWSHRSOHZRXOGWU\DQ\WKLQJWRVDYHWKHOHJ´ (22) 351 
³,GHILQLWHO\ZRXOd have had the amputation at the same time point. My pain got so bad, I could not 352 
ZDON´ (22) 353 
Patients with amputations also reported that meeting with the prosthetics specialists, and spending 354 
some time familiarising themselves with the rehabilitation services available, prior to the amputation 355 
would have helped their recovery (22). 356 
 357 
Three main subthemes emerged in relation to shared decision making in this review; these were lack 358 
of knowledge, expectations and communication barriers. 359 
Several patients reported lack of information about the disease and its progress (16).  Exercise 360 
therapy was recommended for some patients with claudication or post-operatively, however, patients 361 
did not understand the importance and relevance of this therapy, and some decided to do the 362 
opposite and avoid walking (15, 16, 17).  This was mainly because of communication barriers 363 
between clinicians and patients. 364 
³:KHQ,ZDVLQWKHODVWWLPHKHVXUJHRQwas talking to a lady doctor and he said I was needing more 365 
EXWKHVWDUWHGWDONLQJIXQQ\ZRUGVWKDW,GLGQRWXQGHUVWDQG´ (16) 366 
 367 
³:KLOH,ZDVWROG,KDGDUWHU\GLVHDVH,ZDVQ¶WWROGWKDW,FRXOGORVHP\OHJ,ZRXOGKDYHWDNHQEHWWHU368 
FDUHRIP\VHOI´ (22) 369 
 370 
However, sometime this was because of lack of engagement by the patients and handing control over 371 
decision-making to the clinicians.  372 
³7KHOLNHVRI>VXUJHRQV@WKH\NQRZZKDWWKH\DUHWDONLQJDERXWWKH\GRQ¶WVD\WKLQJVXQOHVVWKH\DUH373 
sure so I accept ZKDWWKH\ZDQWWRGR´ (15) 374 
 375 
Patient expectation was also a significant issue. Some had no knowledge of the overall impact of the 376 
atherosclerosis on their health generally, and others expected the intervention to fully cure the 377 
disease. Although most patients reported satisfaction with their intervention some were disappointed 378 
with the results post-operatively as they expected to be back to their pre-disease state with no 379 
symptoms or disability (15-16, 18, 22). 380 
Triangulation 381 
The identified themes were compared to items from validated PROMs that were identified in a recent 382 
study (8). These PROMs include peripheral artery disease quality of life questionnaire (PADQOL), 383 
vascular quality of life questionnaire (VascuQoL), Australian vascular quality of life index 384 
(AUSVIQUOL), peripheral artery questionnaire (PAQ), Intermittent claudication questionnaire (ICQ), 385 
walking impairment questionnaire (WIQ), EuroQoL-5D (EQ-5D-3L), Nottingham health profile (NHP) 386 
and Medical outcomes study 36-item short form (SF-36 ®). Two reviewers examined the overlap 387 
between the themes in the qualitative review and items in the validated PROMs; when there was 388 
complete overlap between the theme and an item in a PROMs an agreement score (+) was awarded; 389 
however, when the theme is covered in a general question a partial agreement score was awarded 390 
(+/-). For instance, EQ-5D has a domain about pain, this domain overlaps completely (is in agreement 391 
(+)) with the pain theme; the same domain overlaps with themes such as pain on walking, rest pain, 392 
night pain and phantom pain; although this domain in EQ-5D-3L does not ask about them specifically. 393 
When the theme is not covered at all a silence score (-) was awarded; for example, in EQ-5D-3L there 394 
is no questions about sexual functioning or altered sensation.  395 
The best generic PROMs that captured all the important issues for patients with PAD was the NHP 396 
and the disease specific PROMs with the best fit with the themes from the qualitative review was the 397 
VascuQoL. However, VascuQoL did not cover issues important to patients who had an amputation 398 
secondary to PAD.  399 
WIQ only covered important symptoms, whereas ICQ only covered some of the themes important to 400 
patients with intermittent claudication. For further details on the results of triangulation see table 4. 401 
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 403 
Discussion 404 
 405 
We identified thirty-five themes associated with quality of life for those with different forms of PAD. 406 
These themes were divided into six groups: symptoms, physical functioning, impact on social 407 
functioning, psychological impact, financial impact and process of care 408 
Measuring quality of life for people with PAD including patients with IC, CLI and amputation is of 409 
interest currently because of the introduction of new treatment modalities such as drug eluting stents 410 
and drug coated balloon angioplasty, as well as emerging evidence from trials comparing bypass 411 
operation to endovascular therapies.   Outcome measures, such as limb salvage, patient survival, 412 
patency of bypass or vascularised artery, and re-intervention rates, have been used to compare 413 
outcomes between therapies for patients with PAD, and to inform decision making for patients with 414 
PAD. However, quality of life and functional status is what matters the most to patients (23, 24).  415 
 416 
One of the strengths of this study is that the qualitative review included studies of patients with 417 
different manifestations of PAD, as PAD can present with a spectrum of symptoms, and with varying 418 
severity. The inclusion in the review of patients with IC, CLI and amputation ensured that the variation 419 
of impacts on QoL were captured. This is important due to the complexity of PAD presentation, since 420 
patients could have IC or CLI or had an amputation in one leg and suffer from a different stage of the 421 
disease in the other leg. Validated PROMs in this field cover only a stage of the disease.  A 422 
comprehensive measure can be used to examine the outcomes of patients at different stages of the 423 
disease.  424 
 425 
This review incorporated evidence from a previous systematic review (8) also conducted by the same 426 
research team, which identified PROMs validated for use with patients with PAD. In the triangulation 427 
section of this study the themes from this qualitative review were mapped against the domains from 428 
the validated generic and disease specific PAD PROMs that were identified in the separate review.  429 
 430 
The main limitations of this study are that some of the included papers in the qualitative review did not 431 
specify the severity of PAD in the patients included.  In other studies, the investigators reported the 432 
severity but did not distinguish between the themes based on the type of PAD. Furthermore, there 433 
was only one study that reported on the quality of life of patients with PAD related amputation.   434 
 435 
The review identifiHGWKHLPSRUWDQWV\PSWRPVIURPWKHSDWLHQWV¶SHUVSHFWLYHWKHVHLQFOXGHGSDLQ436 
altered sensation, cold extremities, fatigue/weakness, issues of mobility, ulcers, sexual functioning 437 
and symptom progression.  This study also revealed that patients with critical ischaemia and 438 
intermittent claudication post-intervention complained from some of these symptoms with varying 439 
degree. Furthermore, many patients with critical ischaemia expressed their views that quality of life 440 
and severity of symptoms should be considered when deciding the timing and type of intervention 441 
whether that is revascularisation or amputation.   442 
 443 
Amongst some academic and clinical circles quality of life has confusingly come to be known as 444 
anything which is not clinical (25). However, this review indicates that, when patients with PAD are 445 
asked, the distress related to symptoms is integral to their quality of life, and in some instances seeing 446 
beyond the distress of pain and lack of mobility is difficult. The type of pain, its onset, as well as 447 
location, was different depending on the severity of disease; the same applied to fatigue, weakness, 448 
altered sensation and mobility. Mobility issues were different between a patient post amputation, and 449 
someone with claudication; however, the issue remained relevant to both groups. 450 
 451 
Issues relating to impact on psychological wellbeing included the following subthemes: lack of control 452 
over life, negative impact on self-esteem, self- perception, impact on mood, fear of amputation, loss of 453 
independence and death. The impact of these problems differed between patients depending on the 454 
whether they suffered with claudication symptoms only, if they had severe ischaemia, or if they had 455 
undergone an amputation.  456 
 457 
One of the strongest finding of this study is that when the themes generated from the review were 458 
mapped against the generic and disease specific PROMs validated in patients with PAD, none of 459 
them covered all the important issues revealed by the review. This is likely because the review 460 
included studies that interviewed patients with IC, CLI  and PAD related amputations; therefore 461 
including all the themes important to patients with symptomatic PAD.  This provides important 462 
evidence for critically examining the content of PROMs currently being used in patients with PAD and 463 
particularly the generic measures such as EQ-5D-3L and SF-36.   464 
 465 
Both PROMs are used commonly to inform resource allocation decisions as well monitoring quality of 466 
life. There are several concerns with generic PROMS for instance EQ-5D-3L & SF-36 were designed 467 
by experts with no input from patients with PAD and their coverage does not include all the important 468 
issues to patients with IC, CLI and amputation secondary to PAD. The EQ-5D-3L has five dimensions 469 
of health: mobility, self-care, usual activities, pain and discomfort, and depression and anxiety. 470 
Respondents are asked to report their level of problems (no problems, slight/moderate problems or 471 
severe/extreme problem) on each dimension to provide an overall score for the health state. A key 472 
concern raised about this measure is the focus on physical health with little focus of psychological 473 
wellbeing.  474 
 475 
The findings of this study can help to provide useful evidence for examining the content validity of 476 
different measures. This evidence can be used alongside quantitative psychometric evidence to 477 
design a new disease specific measure. Our group designed this instrument and aim to perform factor 478 
analysis and well as further psychometric analysis in a large survey of patients with PAD. 479 
 480 
 481 
³'DWD$YDLODELOLW\6WDWHPHQW´ 482 
The analysis data cannot be shared since some of the papers included in the systematic review have 483 
copy rights and these prohibit publishing them in other journals but allow researchers to use them for 484 
secondary analysis. These papers were uploaded into the software in which we performed the 485 
analysis. Supplementary materials are included regarding the search strategy and analysis.  486 
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